Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Receives Consensus Recommendation of “Hold” from Analysts

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) has been given an average rating of “Hold” by the eleven ratings firms that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation and five have issued a buy recommendation on the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $10.28.

A number of analysts have recently weighed in on MRVI shares. Royal Bank of Canada lowered their target price on Maravai LifeSciences from $17.00 to $13.00 and set an “outperform” rating for the company in a research note on Friday, November 8th. Wolfe Research started coverage on Maravai LifeSciences in a research note on Thursday, November 14th. They issued a “peer perform” rating for the company. William Blair restated a “market perform” rating on shares of Maravai LifeSciences in a research note on Friday, November 8th. Robert W. Baird lowered their target price on Maravai LifeSciences from $10.00 to $9.00 and set an “outperform” rating for the company in a research note on Friday, November 8th. Finally, Guggenheim began coverage on Maravai LifeSciences in a research report on Thursday, December 19th. They issued a “neutral” rating for the company.

Maravai LifeSciences Stock Performance

Shares of NASDAQ:MRVI opened at $4.85 on Friday. Maravai LifeSciences has a twelve month low of $4.28 and a twelve month high of $11.56. The firm has a market cap of $1.22 billion, a PE ratio of -2.96 and a beta of -0.07. The company has a debt-to-equity ratio of 0.89, a quick ratio of 9.94 and a current ratio of 10.74. The business has a fifty day moving average of $5.65 and a 200-day moving average of $7.40.

Insider Transactions at Maravai LifeSciences

In other news, insider Carl Hull purchased 175,000 shares of Maravai LifeSciences stock in a transaction on Monday, November 11th. The stock was purchased at an average price of $5.64 per share, with a total value of $987,000.00. Following the transaction, the insider now directly owns 175,000 shares in the company, valued at $987,000. The trade was a ? increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link. Corporate insiders own 0.63% of the company’s stock.

Institutional Investors Weigh In On Maravai LifeSciences

Large investors have recently made changes to their positions in the stock. JPMorgan Chase & Co. boosted its holdings in shares of Maravai LifeSciences by 1,172.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 4,050,245 shares of the company’s stock valued at $33,658,000 after buying an additional 3,731,924 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Maravai LifeSciences by 30.1% in the 2nd quarter. Bank of New York Mellon Corp now owns 506,413 shares of the company’s stock valued at $3,626,000 after buying an additional 117,120 shares during the last quarter. Dragoneer Investment Group LLC acquired a new stake in shares of Maravai LifeSciences in the 2nd quarter valued at approximately $5,373,000. Royce & Associates LP boosted its holdings in shares of Maravai LifeSciences by 130.4% in the 3rd quarter. Royce & Associates LP now owns 908,778 shares of the company’s stock valued at $7,552,000 after buying an additional 514,332 shares during the last quarter. Finally, Mackenzie Financial Corp boosted its holdings in shares of Maravai LifeSciences by 16.8% in the 2nd quarter. Mackenzie Financial Corp now owns 5,860,641 shares of the company’s stock valued at $41,962,000 after buying an additional 844,325 shares during the last quarter. Institutional investors and hedge funds own 50.25% of the company’s stock.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.